Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax

The Bcl-2 family inhibitors venetoclax and navitoclax demonstrated potent antitumor activity in chronic lymphocytic leukemia patients, notably in reducing marrow load and adenopathy. Subsequent trials with venetoclax have been initiated in non-Hodgkin's lymphoma and multiple myeloma patients. T...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pharmacol Res Perspect
Asıl Yazarlar: Ackler, Scott, Oleksijew, Anatol, Chen, Jun, Chyla, Brenda J, Clarin, Jerry, Foster, Kelly, McGonigal, Thomas, Mishra, Sasmita, Schlessinger, Sally, Smith, Morey L, Tahir, Stephen K, Leverson, Joel D, Souers, Andrew J, Boghaert, Erwin R, Hickson, Jonathan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Ltd 2015
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4618648/
https://ncbi.nlm.nih.gov/pubmed/26516589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.178
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller